News - trametinib


Current filters:


Popular Filters

Pfizer and GSK link up to trial combo melanoma therapy

Pfizer and GSK link up to trial combo melanoma therapy


Two of the world’s pharma giants, USA-based Pfizer and the UK’s GlaxoSmithKline have joined forces…


FDA approves two GSK melanoma drugs and bioMerieux companion diagnostic


The US Food and Drug Administration yesterday (May 29) approved two new oral drugs from UK pharma giant…

BioMerieuxdabrafenibGlaxoSmithKlineMekinistNorth AmericaOncologyPharmaceuticalRegulationTafinlartrametinib

J&J's daratumumab gets "Breakthrough" status; GSK's trametinib delayed by FDA


The US Food and Drug Administration has granted "Breakthrough Therapy Designation" for health care giant…

daratumumabGenmabGlaxoSmithKlineJanssenJohnson & JohnsonNorth AmericaOncologyPharmaceuticalRegulationtrametinib

GlaxoSmithKline initiates Ph III study to test dabrafenib and trametinib combo for BRAF positive melanoma


UK pharma giant GlaxoSmithKline (LSE: GSK) has initiated COMBI-AD, a Phase III study evaluating the combination…

BiotechnologydabrafenibGlaxoSmithKlineJapan TobaccoOncologyPharmaceuticalResearchtrametinib

GlaxoSmithKline files for EU and US approval for dabrafenib and trametinib


UK pharma giant GlaxoSmithKline (LSE: GSK) last week submitted regulatory filings in the European Union…

dabrafenibEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationtrametinib

MEK inhibitors: new weapon in the fight against melanoma


Cancer cell signaling has long been an attractive target for oncology drug development. Increased activation…


More news from ASCO meeting


More positive late-stage clinical data continued to roll out at the Annual Meeting of the American Society…

AlimtaBayerdabrafenibEli LillyGlaxoSmithKlineOncologyPharmaceuticalregorafenibResearchtrametinib

Malignant melanoma drug market to grow more than seven-fold to $1.5 billion in 2020


The market for malignant melanoma drugs is forecast to expand more than seven-fold over the next decade,…

dabrafenibGlobalMarkets & MarketingOncologyPharmaceuticaltrametinibYervoyZelboraf

Back to top